IP Group is an investment company which helps to create, build and support IP-based companies internationally. The group focuses on companies that meaningfully contribute to a healthier,  tech-enriched, regenerative future. IP Group is mostly active in the UK, with an international footprint through investment platforms in Australia, New Zealand and the US.

1. IP Group offers access to potentially disruptive innovations.

IP Group allows investors to tap into the vast opportunity set of early-stage, innovative, private companies, including university spin-outs. We believe these projects pursue some of the most compelling investment themes over the next decade, spanning healthtech, deeptech (across applied AI, next-generation networks, human-machine interface and quantum computing, among others) and cleantech in areas, such as hydrogen, nuclear fusion and electric vehicles. IP Group’s technical know-how, market knowledge, global relationships and evergreen structure make it well suited to support innovative businesses. The company is now focused on doubling down on a narrow set of more mature, growth-stage businesses to generate returns.

2. IP Group’s management sees a strong exit pipeline ahead.

IP Group continues to deliver a meaningful level of realisations, which fuel NAV-accretive share repurchases. Its portfolio includes a number of companies with good business traction and interest from potential buyers. Its management reiterated the target of delivering over £250m in realisation proceeds between FY25 and FY27, which excludes any potential exit proceeds from its holding in the listed Oxford Nanopore.

3. IP Group may generate significant income from the IP it owns.

Beyond its equity investments, IP Group may benefit from being the owner of intellectual property rights. A recent major highlight in this respect was Pfizer’s acquisition of Metsera. IP Group has the potential to generate considerable income from the IP related to anti-obesity drug programmes that it owns and exclusively licenses to Zihipp, which Metsera acquired in 2023. Metsera’s drug candidates represent a multi-billion dollar revenue opportunity, of which IP Group may receive a low-single-digit percentage amount of royalty income, on top of which it will collect technical and commercial milestone payments, as well as an earn-out related to its previous equity investment in Zihipp if the drug passes through clinical trials and is successfully commercialised.

4. Scale-up capital to support companies in their rapid growth phase.

IP Group aims to expand its ecosystem by growing its fee-generating third-party capital under management. This would allow IP Group to better support its portfolio companies beyond the early development stage. Management recently highlighted good traction of scale-up capital discussions. The prospect of allocating at least 5% of defined contribution funds to unlisted equities by 2030, according to the Mansion House Compact signed by major UK pension firms, represents a potential significant tailwind.

Published 10 February 2026